Roche buys GenMark for $1.8 million to challenge test rivals
ZURICH (Reuters) – Roche is filling a testing portfolio gap by buying U.S.-based GenMark Diagnostics in a $1.8 billion deal that the Swiss pharmaceuticals manufacturer said taps one of the fastest-growing diagnostics areas.
